



CHIMERIC THERAPEUTICS

20
26

CHIMERIC

PIONEERS IN CELL THERAPY

TechKnow 2026





DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided

prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.



INVESTMENT OVERVIEW

3

3 Phase 1 clinical trials
under 3 FDA INDs at 6 leading US centres



Multiple clinical updates
in the next 6mths



Experienced leadership team
in cell therapy clinical development



CHM-CDH17
the FIRST CDH17 CAR-T in clinical trials



Robust and long life
patent portfolio

CORPORATE PROFILE

Exchange	ASX: CHM
Share Price	\$0.036
52 Week Range	\$0.036 – 0.40
Market Cap	~ 3.1m
Shares on issue	~59m
IPO 2021	



CHM: FOCUSED PORTFOLIO

2 Novel cell therapies; 3 Clinical Trials

CHM CDH17
CAR-T

Technology from:
 **Penn**
UNIVERSITY of PENNSYLVANIA

PHASE 1/2 TRIAL OPEN
4 sites active

CHM CORE-NK
'OFF THE SHELF' NK

Technology from:
 **CASE
WESTERN
RESERVE**
UNIVERSITY

PHASE 1B TRIAL
OPEN
MD Anderson

PHASE 1B TRIAL
SUSPENDED
Case Western



CHM CDH17

Clinical Trial Update




ASX:
CHM




ENCOURAGING PRE-CLINICAL RESULTS


CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models




NEUROENDOCRINE TUMOURS



GASTRIC CANCER



PANCREATIC CANCER



CHM CDH17
CAR-T



Source: Feng et al., Nature Cancer, 2022



CHM CDH17 CAR-T PHASE 1 RECRUITING

The first CDH17 CAR T cell therapy in clinical trials globally

CHM CDH17
CAR-T

Technology from:



PHASE 1/2 TRIAL OPEN

4 sites actively recruiting

NCT06055439

PERSONALISED CAR-T: AUTOLOGOUS

4 sites actively recruiting: Sarah Cannon, UPenn, UChicago, Emory

FDA IND November 2023

First Patient Dosed August 2024

FASTRACK Designation April 2025: Neuroendocrine Tumours

ORPHAN Designation December 2025: Gastric Cancer

Manufacturing: 15/15 successful runs; GMP Compliant


16 Patients enrolled:

14 Patients treated, 1 awaiting dosing

N= up to 15 evaluable patients




Phase 1/2 Clinical Trial of CHM CDH17



NCT06055439




CHM CDH17 PROGRESS AS AT JULY 21, 2026



NCT06055439



CHM CDH17 PROGRESS AS AT JULY 21, 2026



BEFORE Treatment



DL2 150million cells

AFTER Treatment

Images shared with consent



TOTAL GLOBAL MARKET SIZE





CHM CDH17

12

CHM CDH17 CHM 2101

14 patients treated, 1 awaiting treatment

15/15 manufacturing runs

Anti-tumour activity observed

No safety issues to date

No off-target effects

FY27 Deliverables

Complete Dose level 2

Commence Dose level 3

Conclude Phase 1

Phase 2 readiness



CHM CORE NK

Clinical Trial Update





CHM CORE-NK 2 PHASE 1B TRIALS OPEN

Phase 1b clinical trials OPEN

CHM CORE-NK
'OFF THE SHELF' NK

Technology from:

 **CASE
WESTERN
RESERVE**
UNIVERSITY

PHASE 1B TRIAL
OPEN

PHASE 1B TRIAL
SUSPENDED

OFF THE SHELF: ALLOGENEIC

NK cell expansion platform: **Universal Donor**

Positive Phase 1A Clinical Trial in AML

Two ongoing Phase 1B Clinical Trials in AML

MDACC AML: Cohort 1 cleared, moved to dose expansion for Cohort 2
FRONTLINE - A FIRST IN CELL THERAPY
Multiple Patient dosed; rapidly recruiting

Case Western AML: Trial suspended due to IL-2 Shortage




AML PHASE 1B CLINICAL TRIAL OPEN

CHM CORE-NK + AZA + VEN in FRONTLINE AML

Clinical Trials.gov Identifier: NCT05834244

THE UNIVERSITY OF TEXAS
MDAnderson
~~Cancer~~ Center



CORE NK CELLS



FDA REGISTERED
CHEMOTHERAPY




FDA REGISTERED
BLOOD CANCER DRUG

○ ●
CHM CORE NK
'OFF THE SHELF' NK



CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS



Complete Response means that all visible or measurable signs of cancer have disappeared after treatment



CHM CORE-NK

CHM CORE-NK

'OFF THE SHELF' NK

Investigator Sponsored Trial – MD ANDERSON

Dose Escalation completed

First Line Dosing Underway – up to 20 patients

No safety issues to date

FY27 Deliverables

Complete dosing of 20 patients; subject to MD Anderson



SUMMARY

CHM CDH17

CHM 2101

14 patients treated

15/15 manufacturing runs

Tumour shrinkage observed 10

No unexpected safety issues to date

No off-target effects

CHM CORE-NK

'OFF THE SHELF' NK

Investigator Sponsored Trial – MD ANDERSON

Dose Escalation completed

First Line Dosing Underway

No safety issues to date



CHIMERIC

PIONEERS IN CELL THERAPY

investors@chimerictherapeutics.com

ASX:
CHM

